Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the ...

Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

A 3D illustration of a transfer RNA molecule hovering over a messenger RNA. Transfer RNA acts as an adaptor to convert messenger RNA codons into amino acids during protein synthesis. Credit: ...

61 codons specify one of the 20 amino acids that make up proteins 3 codons are stop codons, which signal the termination of protein synthesis Importantly, the genetic code is nearly universal, shared ...